BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma

Modern Pathology

Volumn 25, Issue 5, 2012, Pages 740-750

  McAlpine, Jessica N ^a   Porter, Henry ^a   Köbel, Martin ^b   Nelson, Brad H ^c   Prentice, Leah M ^c   Kalloger, Steve E ^a   Senz, Janine ^c   Milne, Katy ^c   Ding, Jiarui ^c   Shah, Sohrab P ^c   Huntsman, David G ^c   Gilks, C Blake ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

BRCA1; BRCA2; high grade serous; immune infiltrates; methylation; somatic and germline mutations; TP53

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; MESSENGER RNA; PACLITAXEL; PLATINUM; PROTEIN P53;

ADULT; ARTICLE; ASCITES; CELL INFILTRATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METHYLATION; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVARY CARCINOMA; PRIORITY JOURNAL; SOMATIC MUTATION;

AGED; BRCA2 PROTEIN; CYSTADENOCARCINOMA, SEROUS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84860456671     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.211     Document Type: Article

References (64)

1. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-953.
2. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. (Pubitemid 43048949)
3. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008;39:1239-1251.
4. Ayhan A, Gultekin M, Taskiran C, et al. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer 2007; 17:68-75. (Pubitemid 46213972)
5. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advancedstage ovarian cancer. Obstet Gynecol 2006;107:77-85.
6. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103:559-564. (Pubitemid 44602167)
7. Chi DS, Palayekar MJ, Sonoda Y, et al. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. Gynecol Oncol 2008;108:191-194. (Pubitemid 350299443)
8. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006;103:1083-1090. (Pubitemid 44821338)
9. Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001;82:532-537. (Pubitemid 32826455)
10. Sigurdsson K, Alm P, Gullberg B. Prognostic factors in malignant epithelial ovarian tumors. Gynecol Oncol 1983;15:370-380. (Pubitemid 13105423)
11. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxelbased chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-2465. (Pubitemid 46606325)
12. Gadducci A, Katsaros D, Zola P, et al. Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2). Int J Gynecol Cancer 2009;19:615-619.
13. Köbel M, Kalloger SE, Santos JL, et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecolc Oncol 2010;116:50-56.
14. Winter III WE, Maxwell GL, Tian C, et al. Prognostic factors for III stage epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621-3627. (Pubitemid 47372600)
15. Dressman HK, Berchuck A, Chan G, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2007;474:609-615.
16. Köbel M, Reuss A, Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010;222:191-198.
17. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010;221: 49-56.
18. Milne K, Köbel M, Kalloger SE, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PloS One 2009;4: e6412.
19. Clarke B, Tinker AV, Lee CH, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009;22:393-402.
20. Han LY, Fletcher MS, Urbauer DL, et al. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008;14:3372-3379.
21. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213. (Pubitemid 36077915)
22. Leffers N, Gooden MJ, de Jong RA, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009;58: 449-459.
23. Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 2008;222:101-116. (Pubitemid 351430376)
24. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-18543. (Pubitemid 43011261)
25. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-1706. (Pubitemid 44942707)
26. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17.
27. Hennessy BT, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010;28:3570-3576.
28. Hilton JL, Geisler JP, Rathe JA, et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002;94:1396-1406. (Pubitemid 35154144)
29. Geisler JP, Hatterman-Zogg MA, Rathe JA, et al. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002;94:61-67. (Pubitemid 34082844)
30. Mukhopadhyay A, Curtin N, Plummer R, et al. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine. Br J Obstet Gynaecol 2011;118:429-432.
31. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 2009;4:461-487.
32. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002;8:571-576. (Pubitemid 35408215)
33. Karran P. DNA double strand break repair in mammalian cells. Curr Opin Gen Dev 2000;10:144-150. (Pubitemid 30182246)
34. Tassone P, Di Martino MT, Ventura M, et al. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 2009;8:648-653.
35. Powell SN, Kachnic LA. Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med Chem 2008;8:448-460. (Pubitemid 351761429)
36. Chirnomas D, Taniguchi T, de la Vega M. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006;5: 952-961. (Pubitemid 43724595)
37. Snyder ER, Ricker JL, Chen Z, et al. Variation in cisplatinum sensitivity is not associated with Fanconi anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines. Cancer Lett 2007;245:75-80. (Pubitemid 44959341)
38. Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-23903. (Pubitemid 30624678)
39. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006; 5:135-142. (Pubitemid 43824469)
40. Di Leo A, Claudino WM, Pestrin M, et al. Using specific cytotoxics with a targeted mind. Breast 2007;16:S120-S126.
41. Moule R, Sohaib A, Eeles R. Dramatic response to platinum in a patient with cancer with a germline BRCA2 mutation. Clin Oncol 2009;21:444-447.
42. Tan DS, Rothermundt C, Thomas K. 'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008;26:5530-5536.
43. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335:1413-1416. (Pubitemid 26382501)
44. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-2195. (Pubitemid 36444059)
45. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260-2265. (Pubitemid 30246777)
46. Gallagher DJ, Konner JA, Bell-McGuinn KM. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol 2011;22:1127-1132.
47. Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Gen 2007;81:873-883. (Pubitemid 47580242)
48. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-813.
49. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-1760.
50. Goya R, Sun MG, Morin RD, et al. SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics 2010;26:730-736.
51. Li H, Handsaker B, Wysoker A, et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009;25:2078-2079.
52. Wiley A, Katsaros D, Chen H, et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006;107:299-308. (Pubitemid 44036559)
53. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
54. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev 2010;10:803-808.
55. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010;34:1407-1416.
56. Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010;20:945-952.
57. Bolton KL, Goh C, Ramus S, et al. Genetic heterogeneity of ovarian cancer survival effects in BRCA1/2 germline mutations: a large, multi-center study. Thesis 2011.
58. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-lable, nonrandomised study. Lancet Oncol 2011;12:852-861.
59. Adams SF, Levine DA, Cadungog MG, et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009;115:2891-2902.
60. Cannistra SA. BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease. Clin Cancer Res 2007;13:7225-7227.
61. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007;13: 7413-7420.
62. Sakai W, Swisher EM, Jacquemont C, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 2009;69:6381-6386.
63. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451:1116-1120. (Pubitemid 351317449)
64. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008;451:1111-1115. (Pubitemid 351317441)